Genomics

Dataset Information

0

Transcriptional differentiation of Trypanosoma brucei during in vitro acquisition of resistance to acoziborole


ABSTRACT: Purpose: Acoziborole is a recently developed benzoxaborole class compound, currently in clinical trials, for stage 1 and stage 2 treatment of Human African Trypanosomiasis. Recent studies have made significant progress in determining the molecular mode of action of acoziborole. However, less is known about the potential mechanisms leading to acoziborole resistance in trypanosomes. By characterising in vitro drug-resistance, this study aimed to gain a better understanding of the mechanisms involved in acoziborole resistance in the clinicaly relevant Trypanosoma brucei Methods: Drug resistance was generated in vitro through incremental dosage of acoziborole. RNA was isolated from axenic cultures of drug-resistant and parental drug sensitive cells and submitted for RNA-seq Results: Transcriptomics analysis revealed widepread downregulation of transcripts associated with mammalian-infective bloodstream-form parasites. Conversely, transcripts associated with insect-stage procyclic form parasites were increased, indicating that the resistant cells had undergone an unspecified "differentiation event", albeit on a transcriptomic level Conclusions: Trypanosoma brucei resistance to acoziborole can be generated under in vitro axenic conditions, and "transcriptional differentiation" is a mechanism of resistance. However, it is unknown whether this phenomenon is relevant to an in vivo setting

ORGANISM(S): Trypanosoma brucei brucei

PROVIDER: GSE168394 | GEO | 2021/03/07

REPOSITORIES: GEO

Similar Datasets

2020-09-18 | GSE147734 | GEO
2020-02-26 | GSE143456 | GEO
2024-02-19 | GSE249623 | GEO
2021-01-22 | GSE165290 | GEO
2018-10-01 | GSE114810 | GEO
2021-07-20 | MTBLS2372 | MetaboLights
2015-01-23 | PXD001082 | Pride
2022-08-29 | GSE200642 | GEO
2020-05-08 | GSE140796 | GEO
2007-07-04 | GSE8369 | GEO